Ectodermal Dysplasia, Anhidrotic, With T-Cell Immunodeficiency, Autosomal Dominant
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Ectodermal Dysplasia, Anhidrotic, With T-Cell Immunodeficiency, Autosomal Dominant
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Anhydrotic Ectodermal Dysplasias
|
0.120 |
Biomarker
|
disease |
HPO |
|
|
|
Hypodontia
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Anhidrosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hypohidrosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Frontal bossing
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Intolerant of heat
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Saddle nose
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Peg-shaped teeth
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Sparse hair
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Recurrent infection of the gastrointestinal tract
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Aplasia of the sweat glands
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Recurrent respiratory infections
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Defective production of NFKB1-dependent cytokines
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Herpes Simplex Infections
|
0.010 |
Biomarker
|
group |
LHGDN |
Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes.
|
16407234 |
2006 |
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hyperglycaemia reduced LPS-induced mRNA expression of nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha (NFKBIA), interleukin-1 alpha (IL1A) and chemokine (C-C motif) ligand 3 (CCL3), whereas during hyperinsulinaemia enhanced mRNA levels occurred in six out of eight measured inflammation-related genes, irrespective of plasma glucose levels.
|
18290856 |
2008 |
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Virus infection does not appear to alter the amount of RelA (p65) or NFKB1 (p50) but rather affects the capacity of I kappa B alpha to sequester RelA (p65), therefore leading to constitutive levels of RelA DNA binding activity and to increased levels of NF-kappa B-dependent gene activity.
|
8394446 |
1993 |
Squamous cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death.
|
10423407 |
1999 |
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas.
|
11059688 |
2000 |
Rheumatoid Arthritis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
IkappaBalpha promoter polymorphisms in patients with rheumatoid arthritis.
|
17284228 |
2007 |
Lupus Erythematosus, Systemic
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
I kappa B alpha promoter polymorphisms in patients with systemic lupus erythematosus.
|
18071880 |
2008 |
Lupus Erythematosus, Systemic
|
0.030 |
GeneticVariation
|
disease |
LHGDN |
I kappa B alpha promoter polymorphisms in patients with systemic lupus erythematosus.
|
18071880 |
2008 |
Primary Sjögren's syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
IkappaBalpha promoter polymorphisms in patients with primary Sjögren's syndrome.
|
18600435 |
2008 |
Ankylosing spondylitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
IkBα promoter polymorphisms in patients with ankylosing spondylitis.
|
19363678 |
2009 |